The firm's technology uses red blood cell-bound nucleic acids to identify clinically actionable disease signals in oncology.

The effort, called SepTech, will begin on Sept. 1 and run through August 2029, and it picks up from an earlier project called ECLIPSE.

Last week, readers were most interested in a story about how the launch of Roche's Cobas Mass Spec solution in the US could turn the market on its head.

NEW YORK – Using technology developed at Johns Hopkins University, startup Hypermelt aims to develop tests for the early detection of cancer with improved sensitivity over existing technologies. To ...

The mass spectrometry-based test is intended as an aid in evaluating individuals with signs of cognitive impairment for the amyloid brain pathology associated with Alzheimer's.

The Rural Health Transformation Program may be an unprecedented boon for healthcare, but diagnostics developers are running the risk of missing out.

Some observers suggest incumbent vendors will adapt to the new competition by using their instruments for higher-value assays, though others anticipate testing consolidation.

The firm recently raised $15 million in seed financing to further validate and commercialize its pathogen detection and antimicrobial resistance profiling platform.

NEW YORK – Roche on Monday announced that its Elecsys Phospho-Tau Plasma (pTau217) blood test for Alzheimer's disease has received clearance from the US Food and Drug Administration. The test supports ...

Last week, readers were most interested in a story about OraSure's withdrawal of an FDA submission and the cancellation of a milestone payment to Sherlock Biosciences.

NEW YORK – Roche announced on Wednesday that it has received US Food and Drug Administration approval for the expanded use of two companion diagnostic tests with Jazz Pharmaceuticals' Ziihera ...

HealthTab will distribute Abbott's Afinion 2 Analyzer in National Health Service-linked pharmacies to test for HbA1c and lipid profiles.